Overview

Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
0
Participant gender:
Female
Summary
Ibandronate is a third-generation biphosphonate with recognized antiresorptive efficacy by several international, randomized, double-blind, controlled trials. These studies have not included patients from central america, to the best of our knowledge. Therefore, this open-label, uncontrolled study, was set out to assess the clinical effects of a 6-m treatment course with Ibandronate plus vitamine D and Calcium on bone mineral density and health-related quality of life.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pontifical Catholic University of Argentina
Treatments:
Calcium, Dietary
Diphosphonates
Ergocalciferols
Ibandronic acid
Vitamin D
Vitamins
Criteria
Inclusion Criteria:

- Women with a diagnosis of osteoporosis of at-Risk

- Have a medical indication to receive Ibandronate+Vitamine D+Calcium

Exclusion Criteria:

- Osteoporosis due to secondary causes